OHR Pharmaceutical, Inc. (OHRP) Analysts See $-0.07 EPS

January 20, 2018 - By Migdalia James

 OHR Pharmaceutical, Inc. (OHRP) Analysts See $ 0.07 EPS
Investors sentiment increased to 1.44 in 2017 Q3. Its up 0.19, from 1.25 in 2017Q2. It increased, as 3 investors sold OHR Pharmaceutical, Inc. shares while 6 reduced holdings. 6 funds opened positions while 7 raised stakes. 4.60 million shares or 16.87% more from 3.93 million shares in 2017Q2 were reported.
Two Sigma Ltd Liability holds 21,733 shares or 0% of its portfolio. Renaissance Technologies Ltd Liability Corp holds 0% or 788,409 shares. Finemark Financial Bank And Trust holds 0% of its portfolio in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 22,589 shares. First Manhattan, a New York-based fund reported 7,215 shares. Salzhauer Michael holds 0.01% or 35,715 shares. Moreover, Cannell Peter B has 0.01% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). The New York-based Prelude Cap Mngmt Limited has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Hightower Advsr Limited Liability Corp has 27,000 shares for 0% of their portfolio. Bryn Mawr Tru stated it has 10,000 shares or 0% of all its holdings. Blackrock has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Vanguard Group holds 0% or 1.13 million shares in its portfolio. Virtu Financial Ltd Liability Corp has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Moreover, California Employees Retirement Sys has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 78,800 shares. 19,935 are held by Deutsche Bankshares Ag. Pnc Fin Grp Incorporated accumulated 20,021 shares.

Analysts expect OHR Pharmaceutical, Inc. (NASDAQ:OHRP) to report $-0.07 EPS on February, 13.They anticipate $0.14 EPS change or 66.67 % from last quarter’s $-0.21 EPS. After having $-0.08 EPS previously, OHR Pharmaceutical, Inc.’s analysts see -12.50 % EPS growth. The stock decreased 2.50% or $0.0089 during the last trading session, reaching $0.3471. About 1.92 million shares traded. OHR Pharmaceutical, Inc. (NASDAQ:OHRP) has declined 77.87% since January 20, 2017 and is downtrending. It has underperformed by 94.57% the S&P500.

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) Ratings Coverage

Among 3 analysts covering Ohr Pharma (NASDAQ:OHRP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Ohr Pharma has $30 highest and $7 lowest target. $15.67’s average target is 4414.55% above currents $0.3471 stock price. Ohr Pharma had 6 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Brean Capital on Wednesday, August 10 to “Hold”. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 16 report. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, October 27. The firm earned “Buy” rating on Friday, August 7 by Brean Capital. Roth Capital downgraded OHR Pharmaceutical, Inc. (NASDAQ:OHRP) on Friday, January 5 to “Hold” rating.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $19.51 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Another recent and important OHR Pharmaceutical, Inc. (NASDAQ:OHRP) news was published by Globenewswire.com which published an article titled: “Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD” on January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.